 Fennec Pharmaceuticals Inc. Nasdaq:FENC; TSX: FRX, a specialty pharmaceutical company, today announced it has completed its rolling submission of a New Drug Application NDA to the U.S. Food and Drug Administration FDA for PEDMARKTM a unique formulation of sodium thiosulfate for intravenous use and submitted a Marketing Authorization Application MAA to the European Medicines Agency EMA for sodium thiosulfate tradename to be determined. The PEDMARKTM indication requested is for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to 18 years of age with localized, non-metastatic, solid tumors. 